Latest profit margin for Spencer Pharmaceutical: -184.63% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2004
Trailing 12 months ending Mar 2004
Spencer Pharmaceutical (SPPH) currently reports a profit margin of -184.63% as of March 2004. That compares with -68.11% in the prior-year period — down 171.1% year over year. That is below the sector sector average of 13.4%. Use the charts on this page to explore Spencer Pharmaceutical's profit margin history and peer comparisons.
Spencer Pharmaceutical's profit margin decreased from -68.11% to -184.63% — a 171.1% year-over-year decrease (period ending March 2004). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Spencer Pharmaceutical's profit margin of -184.63% is lower than the its sector sector average of 13.4%. That is roughly 1477.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Spencer Pharmaceutical's current -184.63% should be judged against industry norms (sector average: 13.4%) and against SPPH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -184.63%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.4%. From there, open related valuation or income-statement pages for Spencer Pharmaceutical, and consider following SPPH for alerts when major investors trade the stock.